

**BIOGRAPHICAL SKETCH**

Give the following information for all new key personnel, consultants, and collaborators.  
Copy this page for each person.

NAME Charles R. Thomas, Jr., M.D.	POSITION TITLE Professor & Chair
--------------------------------------	-------------------------------------

EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
Dartmouth College, Hanover, New Hampshire	B.A.	1979	Biology/Education
University of Illinois, Chicago, Illinois	M.D.	1985	Medicine
Baylor College of Medicine, Houston, Texas	Intern	1986	Internal Medicine
Baylor College of Medicine, Houston, Texas	Residency	1988	Internal Medicine
Rush Medical College, Chicago, Illinois	Fellowship	1991	Medical Oncology
University of Washington, Seattle, Washington	Fellowship	1994	Radiobiology
University of Washington, Seattle, Washington	Residency	1997	Radiation Oncology

RESEARCH AND/OR PROFESSIONAL EXPERIENCE: Concluding with present position, list in chronological order previous employment, experience, and honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on any Federal Government public advisory committee. list, in chronological order, the titles, all authors, and complete references to all publications during the past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED 4 PAGES.

**Personal Statement**

I am a full-time academic clinician & serve as the department chair of the radiation oncology program at a NCI Designated Cancer Center, the Knight Cancer Institute of the Oregon Health & Science University. My translational research involves studying the interactions between novel systemic therapeutics and ionizing radiation. I have interest in the evaluation of mechanisms of radiation treatment-related fatigue.

My clinical research interests include the design and execution of protocols for translational research-based national cooperative group combined modality therapeutic clinical trials involving GI and thoracic solid tumors. I am working to develop strategies to address barriers to participation in cancer clinical trials amongst minority and ethnic populations in the U.S. I have a particular niche interest in the management of patients with mediastinal tumors, primarily thymic neoplasms, as well as cancer emergencies.

My health services research interests involve the development of pipeline strategies to increase the pipeline of highly-qualified investigators from under-represented minority groups into radiologic sciences and cancer medicine.

[http://www.rsna.org/Thomas\\_And\\_Tanyi\\_Vid1.aspx](http://www.rsna.org/Thomas_And_Tanyi_Vid1.aspx)  
[http://www.rsna.org/Thomas\\_And\\_Tanyi\\_Vid\\_2.aspx](http://www.rsna.org/Thomas_And_Tanyi_Vid_2.aspx)  
[http://www.rsna.org/Thomas\\_And\\_Tanyi\\_Vid\\_3.aspx](http://www.rsna.org/Thomas_And_Tanyi_Vid_3.aspx)

I also have interest in patient-provider communication; burnout assessment & management in academic leaders; and the interaction of mentoring and academic productivity

***Professional/Administrative Experience***

11/05 Professor & Chairman, Department of Radiation Medicine, Oregon Health & Science University, Portland, OR  
 11/05 Chief, Radiation Oncology Services, OHSU HealthCare  
 11/05 Member, Clinical Executive Group, OHSU Knight Cancer Institute  
 12/05 Member, Graduate Faculty, School of Medicine, OHSU  
 2/06 Courtesy (Adjunct) Member, Department of Nuclear Engineering & Radiation Health Physics, Oregon State University, Corvallis, OR

**Biographical Sketch:** Charles R. Thomas, Jr., M.D. (continued)**NIH Funding**

NIH Physician Scientist K-12 Award	1993-4
NIH/NCI SWOG Institutional Radiotherapy PI (University of Texas HSC @ San Antonio)	2001-05
NIH/NCI U56 CA 099038-01, Evaluating Cancer Disparities Co-PI (PI, Yadendra Bains) Among Hispanic Communities <a href="http://www3.cancer.gov/rrip/cdrp/PSC_Presentations/LMC_files/frame.htm">http://www3.cancer.gov/rrip/cdrp/PSC_Presentations/LMC_files/frame.htm</a>	2002-06
NIH/NCI 5U10 CA 076001-13, ACOSOG Radiation Oncology Comm Chair Sub-contract thru Duke University	2009-2012
NIH/NCI Student Institute to Stimulate Interest in Radiological Sciences (SISIRS) PAR 12-049 R25 Cancer Education Grants Program	not funded, Subcommittee Manpower & Training Study Section

**Committee Appointments**

Member, LGI Expert Panel, AJCC 8 <sup>th</sup> Edition Cancer Staging Handbook	2014-20117
Chair, Research Study Section, Grants Program Committee, RSNA R&E Foundation	2013-2015
Chair, American College of Surgeons Oncology Group, Radiation Oncology Committee	2009-2012
Member, Research Study Section, Grants Program Committee, RSNA R&E Foundation	2009-2012
Chair, Member, Editorial Board, RADIOGRAPHICS <a href="http://www.radiographics.rsna.org">www.radiographics.rsna.org</a>	2008-present
Chair, GI Abstract Review Panel, 2008 ASTRO Program Committee	2008-2010
Member, Editorial Board, Journal of Gastrointestinal Oncology <a href="http://www.jgio.org/">http://www.jgio.org/</a>	2010
Member, Editorial Board, Journal of Clinical Oncology <a href="http://www.jco.org/misc/edboard.shtml">http://www.jco.org/misc/edboard.shtml</a>	2005-2007
Member, Editorial Board, Journal of Gastrointestinal Cancer <a href="http://ijgc.edmgr.com/">http://ijgc.edmgr.com/</a>	2010
Member, Editorial Board, CA: A Journal for Clinicians <a href="http://caonline.amcancersoc.org/misc/edboard.shtml">http://caonline.amcancersoc.org/misc/edboard.shtml</a>	2007
Member, Editorial Board, Gastrointestinal Cancer Research (GCR) <a href="http://www.isgio.org">http://www.isgio.org</a> <a href="http://www.mygcronline.org/edt_stff.html">http://www.mygcronline.org/edt_stff.html</a>	2006
Associate Editor for Advances in Oncology, Diseases of the Esophagus <a href="http://www.isde.net/journal.htm">http://www.isde.net/journal.htm</a>	2005-present
Chair, Quality Research in Radiation Oncology (QRRO) GI Comm, American College of Radiology <a href="http://www.pcs-acr.org/gi_committee.html">http://www.pcs-acr.org/gi_committee.html</a>	2005
Test Item Writer, American Board of Radiology, Radiation Oncology GI section	2001-2011
Oral Examiner, American Board of Radiology, Radiation Oncology GI section	2006
Member, SWOG Data & Safety Monitoring Committee	2002-2005
SWOG GI Comm. Rep. Rectal & Anal Intergroup Committee GI Intergroup Tumor Site Task Force	2000
Chair, Membership Committee, American Society of Clinical Oncology	2001-2002
Vice-Chair, Southwest Oncology Group Radiation Oncology Committee	2003-2008
Chair, Constitution & Bylaws Comm, Am Soc of Therapeutic Radiology & Oncology	2010-2011
Member, AACR Science Education Committee	2005-2008
Member, AACR-Thomas J. Bardos Science Education Awards for Undergraduate Students Subcommittee	2005

**Honors & Awards**

American Association for Cancer Research Special Minority Scholar Award	2004
Alpha Omega Alpha	2007

**Professional Development**

Program for Chiefs of Clinical Services, Harvard School of Public Health, January 15-27, 2006 (pending)

**Cooperative Group Protocol Development**

## **Biographical Sketch:** Charles R. Thomas, Jr., M.D. (continued)

Study Chair, SWOG-0304 A Phase II Feasibility Translational Research Trial of Induction Chemotherapy followed by Concomitant Chemoradiation followed by Surgical Resection in Patients with Clinical T4 Rectal Cancer, *open 8/1/04, closed 2/1/06*

Study Co-Chair, SWOG-0356 Oxaliplatin plus protracted infusion 5-fluorouracil and radiation therapy for potentially curable esophageal cancer: a phase II trial with molecular correlates, *J Clin Oncol 2011*

Study Chair, SWOG-0414IMC-C225 (Erbix, Cetuximab) plus cisplatin (CDDP), irinotecan (CPT-11), and thoracic radiotherapy (TRT) for locally advanced (non-metastatic), clinically unresectable esophageal cancer: A Phase I/II trial with Molecular Correlates (Study Co-Chair)

Study Co-Chair, SWOG-0533 Pilot trial of concurrent cisplatin/etoposide/bevacizumab (NSC-704865) and radiotherapy followed by consolidation docetaxel/bevacizumab in patients with inoperable locally advanced Stage III non-small cell lung cancer, *manuscript under preparation*

Study Co-Chair, ACOSOG-Z06041 A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer, *Ann Surg Oncol 2011*

Study Co-Chair, SWOG-0920 A Phase II Trial of Baviximab in Combination with Concurrent Chemotherapy and Radiotherapy Followed by Surgical Resection for Non-Small Cell Lung Cancer (NSCLC) Involving the Superior Sulcus (Pancoast Tumors), *Concept approved*

## **Bibliography (since 2012)**

<http://www.ohsu.edu/ohsuedu/academic/som/radmedicine/publications/facultytextbooks.cfm>

Ord CB, Hansen EK, **Thomas CR Jr** (Eds), *Radiation Oncology Study Guide*, Springer, 2013, 300 pp, ISBN 978-1-4614-6399-3, <http://www.springer.com/medicine/radiology/book/978-1-4614-6399-3>

Tomblyn MB, Goldman BH, **Thomas CR Jr.**, Benedetti JK, Lenz H-J, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD: Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase II study of the Southwest Oncology Group (S0414). *J Thorac Oncol* 2012

<http://www.ncbi.nlm.nih.gov/pubmed/22481235>

Konski AA, Suh WW, Herman JM, Blackstock AW Jr, Hong TS, Poggi MM, Rodriguez-Bigas M, Small W Jr., **Thomas CR Jr.**, Zook J: ACR Appropriateness Criteria: Recurrent Rectal Cancer. *Gastrointestinal Cancer Research* 5(1):4-12, 2012

Samuelson BT, Fromme EK, **Thomas CR Jr.**: Changes in spirituality and quality of life in patients undergoing radiation therapy. *Am J Hospice Palliat Med*, 2012

Quigley MR, Ramahi EH, Fuller CD, Choi M, **Thomas CR Jr.**: Distribution of the H-index in therapeutic radiology confirms to a variation of power law: Implications for assessing academic productivity. *J Cancer Education*

<http://www.ncbi.nlm.nih.gov/pubmed/22544537>

Jagsi R, Bekelman J, Brawley O, Deasy JO, Le Q-T, Michalski J, Movsas B, **Thomas CR Jr.**, Lawton CA, Lawrence T, Hahn S: A research agenda for radiation oncology: results of the Radiation Oncology Institute's comprehensive research needs assessment. *Practical Radiat Oncol & Int J Radiat Oncol Biol Phys* 84(2):318-322, 2012

<http://www.ncbi.nlm.nih.gov/pubmed/22436790>

Holliday E, Fuller CD, Wilson LD, **Thomas CR Jr.**: Success breeds success: Authorship distribution in the Red Journal 1975-2011. *Int J Radiat Oncol Biol Phys* 2012 <http://www.ncbi.nlm.nih.gov/pubmed/22560553>

Jones WE III., **Thomas CR Jr.**, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW Jr., Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small Jr W, Zook J, Suh WW: ACR Appropriateness Criteria: Resectable Rectal Cancer, *Radiation Oncology BMC Medicine* 7:161, 2012

<http://www.ro-journal.com/content/pdf/1748-717X-7-161.pdf>

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson A III, **Thomas CR Jr.**, Mayer RJ, Haddock MG, Rich TA, Willett CG.: Long-term update of US G intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving 5FU-mitomycin versus 5FU cisplatin. *J Clin Oncol* 30(35): 4344-4351, 2012

Tsikitis VL, Lu KC, Herzig DO., **Thomas CR Jr.**: Anal cancer squamous cancer: overview, surveillance after treatment and management of local recurrence, *Colorectal Cancer* 1(6):503-511, 2012

Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM., **Thomas CR Jr.**: Quality Research

**Biographical Sketch:** Charles R. Thomas, Jr., M.D. (continued)

- in Radiation Oncology (QRRO) analysis of clinical performance measures in the management of gastric cancer, *Int J Radiat Oncol Biol Phys* 2013, <http://www.sciencedirect.com/science/article/pii/S0360301612034074>
- Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, **Thomas CR Jr.**, Waddell T, Jett JR, Lyss AP, Keller SM, Gandara DR: Induction chemoradiotherapy followed by consolidation cytotoxic therapy for superior Sulcus (Pancoast tumors) non-small cell lung cancer: a Southwest Oncology Group (SWOG)-coordinated feasibility phase II intergroup trial (S0220). Society of Thoracic Surgeons 49<sup>th</sup> Annual Meeting.
- Kaur T, Dolan JP, Diggs BS, Luna R, Sheppard BC, Schipper P, Tieu B, **Thomas CR Jr.**, Gatter K, Vaccaro GM, Hunter JG: Is neoadjuvant therapy beneficial in clinically staged T2N0 esophageal cancer? Proceedings of the 2013 Gastrointestinal Cancers Symposium, San Francisco, Jan 24-26, 2013
- Call JA, Prendergast BM, Jensen LG, Ord CB, Goodman KA, Jacob R, Mell LK, **Thomas CR Jr.**, Jabbour S, Miller RC: Intensity-modulated radiation therapy (IMRT) for anal cancer: Results from a multi-institutional retrospective cohort study. *Am J Clin Oncol* 2014  
<http://www.ncbi.nlm.nih.gov/pubmed/24401669>
- Herman JM, **Thomas CR Jr.**: RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction? *Int J Radiat Oncol Biol Phys* 86(1):8-10, 2013
- Choi M, Holliday EB, Jagsi R, Wilson LD, Fuller CD, **Thomas CR Jr.**: Citation-based estimation of scholarly activity among domestic academic radiation oncologists: 2012 update. *J Radiat Oncol* 2013,  
<http://link.springer.com/article/10.1007/s13566-013-0103-x>
- Eil R, Diggs B, Wang SG Dolan J, Hunter JG, **Thomas CR Jr.**: Nomogram for predicting survival following treatment of resected esophageal cancer based on a SEER-Medicare database. 49<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Chicago. *J Clin Oncol*, 2013
- Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Benson AB III, **Thomas CR Jr.**, Mayer RJ, Haddock MG, Rich TA, Willett CG.: Anal carcinoma (phase III RTOG 98-11): TN category impact on survival, relapse, and colostomy failure. *In press IJROBP* 2013
- Kernstine K, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, **Thomas CR Jr.**, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR: Induction chemoradiotherapy followed by consolidation cytotoxic therapy for superior sulcus (Pancoast tumors) non-small cell lung cancer: a Southwest Oncology Group (SWOG)-coordinated feasibility phase II intergroup trial (S0220). *Submitted to Ann Thorac Surg* 2013
- Rana S, Holliday EB, Jagsi R, Wilson LD, **Thomas CR Jr.**, Fuller CD: Scholastic activity among radiation oncology residents at U.S. academic institutions: a benchmark analysis. *Journal of Cancer Education* 2013,  
<http://www.ncbi.nlm.nih.gov/pubmed/23828146>
- Chapman CH, Hwang W-T, Both S, **Thomas CR Jr.**, Deville C: The current status of diversity in diagnostic radiology: a missed, available pipeline. *Radiology* 2013, *provisional acceptance*
- Barnett A, Cedar A, Siddiqui F, Herzig D, Fowlkes E, **Thomas CR Jr.**: Colorectal cancer emergencies, *J Gastrointest Cancer* 44(2):132-142, 2013, <http://www.ncbi.nlm.nih.gov/pubmed/23371864>
- Chapman CH, Hwang W-T, **Thomas CR Jr.**, Deville C: Current status of diversity in diagnostic radiology: a missed, available pipeline. 9<sup>th</sup> Annual AAMC Physician Workforce Research Conference, Alexandria, VA, May 2-3, 2013
- Chapman CH, Hwang WT, Both S, **Thomas CR Jr.**, Deville C: Current status of diversity by race, Hispanic ethnicity, and sex in diagnostic radiology. *Radiology* July 30, 2013, <http://www.ncbi.nlm.nih.gov/pubmed/23901125>
- Overton LC, **Thomas CR Jr.**, Herzig DO, Lopez CD: Multi-modality therapy for rectal cancer: a review of the past, present and future. *Oncology & Hematology Review* 9(1):26-30, 2013
- Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, **Thomas CR Jr.**: Curative treatment of esophageal cancer: an evidence based review. *J Gastrointest Cancer* 2013, <http://www.ncbi.nlm.nih.gov/pubmed/23824628>
- Duffy RM, Tieu B, **Thomas CR Jr.**: Thymic tumors: a retrospective review of the 10-year OHSU Knight Cancer Institute experience. IMRT. 4<sup>th</sup> International Thymic Malignancy Interest Group Annual Meeting, Bethesda, Sept 6-7, 2013
- Bleyer A, **Thomas CR Jr.**: Breast cancer mortality reduction in the United States during 1969-2009 was independent of screening mammography in its nine geographically dispersed SEER regions: More evidence for less benefit of screening mammography. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Booth D, Waller J, Chen Y, Hedlund S, **Thomas CR Jr.**: Qualitative and quantitative distress assessment of cancer patients using the NCCN distress thermometer. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Bornstein S, Monroe M, Holland J, Watson S, Korkola J, Kulesz-Martin M, Gray J, **Thomas CR**, Wong MH: Investigation of the tumor-initiating cell microenvironment niche in recurrent head & neck squamous cell carcinoma using a novel

**Biographical Sketch:** Charles R. Thomas, Jr., M.D. (continued)

- microenvironment microarray platform. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Deville C, Chapman C, Both, S, Hwang W, **Thomas CR Jr.**: United States radiation oncology residency diversity over the past twenty years. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Holliday EB, Jagsi R, Thomas CR Jr., Wilson LD, Fuller CD: Standing on the shoulders of giants: Initial results from the Radiation Oncology Academic Development and Mentorship Assessment Project (ROADMAP). 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta  
1st place for the Resident Poster Viewing Recognition Award in the Clinical category
- Roach III M, Hunt D, Lawton CA, Hsu ICJ, Lustig RA, Jones CU, Rotman M, Zeitzer KL, Werner-Wasik, Kim H, **Thomas CR Jr.**, Shipley WU, Sandler HM: Radiation Therapy Oncology Group (RTOG) 9413: A randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) & neoadjuvant hormonal therapy (NHT) to adjuvant hormonal therapy (AHT). 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Siddiqui FA, Atkins K, Chennupati S, Hunter JG, Dolan JP, **Thomas CR Jr.**: Retrospective overall survival analysis of neoadjuvant chemoradiotherapy for esophageal cancer at a NCI-Designated Cancer Center. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Thomas CR Jr.**, Garcia-Aguilar J, Chen Y, Avila K, Krieg RM, Bergsland EK, Chu P, Smith DD, Rothenberger DA, & Hwang JM for the Time of Rectal Cancer Response of Chemoradiation Consortium. Phase 2 timing of rectal cancer response to chemoradiation trial: analysis of radiotherapy (RT). 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Wu A, Goodman KA, Chang DT, Hong T, Jabbour S, Kleinberg L, Mamon H, **Thomas CR Jr**, Bosch WR: Generation of a consensus contour atlas for esophageal cancer IMRT. 55<sup>th</sup> Annual Meeting of the American Society of Radiation Oncology (ASTRO), Atlanta
- Tsikitis VL, Lu K, Kim JS, Billingsley KG, **Thomas CR Jr.**, Herzig D: Nomogram for predicting overall and colostomy free survival for patients with anal cancer. Proceedings of the 2014 Gastrointestinal Cancers Symposium, San Francisco, Jan 2014, abstract no. 400
- Tanyi JA, **Thomas CR Jr.**: Student Institute to Stimulate Interest in Radiological Sciences Academic Careers (SISIRSAC): a Novel Near-peer Mentoring Approach. 6<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities & the Medically Underserved, Atlanta, December 6-9, 2013
- Burgos R, Chapman CH, Hwang W-T, Both S, **Thomas CR Jr**, Deville C: Diversity by race, Hispanic ethnicity, and sex of the United States medical oncology workforce. 6<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities & the Medically Underserved, Atlanta, December 6-9, 2013
- Hong TS, Pretz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Jabbour SK, Jones WE 3rd, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, **Thomas CR Jr**, Zook J, Suh WW: ACR Appropriateness Criteria: Anal cancer. *Gastrointest Cancer Res*, Jan 7(1):4-14, 2014 <http://www.ncbi.nlm.nih.gov/pubmed/24558509>
- Eil RL, **Thomas CR Jr.**: New methodology, tools, and protocolized analysis are needed to advance individualized treatment paradigms in esophagea cancer. *Dis Esophagus* 2014  
<http://www.ncbi.nlm.nih.gov/pubmed/24592977>
- Williams TM, Majithia L, Wang SJ, **Thomas CR Jr.**: Defining the role of adjuvant therapy: Cholangiocarcinoma and gallbladder cancer. *Semin Radiat Oncol* 24(2):94-104, 2014  
<http://www.ncbi.nlm.nih.gov/pubmed/24635866>
- Budde C, Nabavizadeh N, Kim J, Lu K, Billingsley K, **Thomas CR Jr.**, Herzig D, Tsikitis VL: Boost Radiation Treatment for Anal Cancer Decreases the Risk for Lifetime Colostomy: Analysis from the National Cancer Data Base (NCDB). *Society of Surgical Oncology* 67th annual meeting, Phoenix, March 12-15, 2014
- Burgos R, Chapman CH, Hwang W-T, Both S, **Thomas CR Jr.**, Deville C: Multi-Decade Assessment of Trends in Graduate Medical Education (GME) Physician Workforce Diversity for Underrepresented Minority Groups in Medicine (URM). 10<sup>th</sup> Annual AAMC Health Workforce Research Conference, May 1-2, 2014 in Washington, D.C., oral presentation
- Ben-Josef E, Guthrie K, El-Khoueiry AB, Corless CL, Zalupski M, Lowy AM, **Thomas CR Jr.**, Alberts SR, Dawson LA, Micetich KC, Thomas MB Siegel AB, Blanke CD: SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA). 50<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Chicago. *J Clin Oncol*, 2014
- Grant MJ, Didier RA, Stevens JS, Beyder DD, Hunter JG, **Thomas CR Jr**, Coakley FV. Radiation-induced liver disease as a mimic of liver metastases at serial PET/CT during neoadjuvant chemoradiation of distal esophageal cancer. *Abdominal Imaging* (In press).
- Mitin T, Enestvedt CK, **Thomas CR Jr.**: Management of oligometastatic rectal cancer: Is liver first?. *J Gastrointest Oncol*, (*In*

**Biographical Sketch:** Charles R. Thomas, Jr., M.D. (continued)

*Press*)

Nabavizadeh N, Simeonova AO, Waller J, Monaco D, Romer JL, Elliott DA, Tanyi A, **Thomas CR Jr.**, Holland J: Volumetric modulated arc radiotherapy for pancreatic malignancies: Dosimetric comparison with sliding-window intensity modulated radiotherapy and three-dimensional conformal radiotherapy. *Medical Dosimetry*, (*In Press*)

Siddiqui FA, Atkins KM, Diggs BS, Holland JM, **Thomas CR Jr.**, Hunter JG, Dolan JP: Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer. *J Gastrointest Oncol*, (*In Press*)

**Research Support**

Physician Scientist K-12 Award 1993-1994  
National Institute of Health  
Role: PI

National Institute of Health/National Cancer Institute 2001-2005  
UTHSCSA SWOG Institutional Radiotherapy Grant  
Role: PI

National Institute of Health/National Cancer Institute 2002-2005  
Evaluating Cancer Disparities Among Hispanic Communities  
RFA-CA-02-002  
Role: Co-PI

National Institute of Health/National Cancer Institute 2008-2010  
ACOSOG Core Grant  
Role: Chair, Radiation Oncology Committee